What's The Future of Cancer Immunotherapy? World Renowned Cancer Expert Shares His Perspective

curncman
Posts: 821
Joined: Fri Jun 26, 2020 8:27 am

When should we consider allo-HSCT in a patient with ALL? And when not?

Post by curncman »

When should we consider allo-HSCT in a patient with ALL? And when not?

curncman
Posts: 821
Joined: Fri Jun 26, 2020 8:27 am

Is AUTO1 CAR T-cell therapy effective in reducing toxicity and enhancing T-cell activation in ALL?

Post by curncman »

Is AUTO1 CAR T-cell therapy effective in reducing toxicity and enhancing T-cell activation in ALL?

curncman
Posts: 821
Joined: Fri Jun 26, 2020 8:27 am

What’s the latest innovation in CAR-T therapy? Fast-off, dual targeting, and other new tricks

Post by curncman »

What’s the latest innovation in CAR-T therapy? Fast-off, dual targeting, and other new tricks

curncman
Posts: 821
Joined: Fri Jun 26, 2020 8:27 am

Future directions for cancer immunotherapy

Post by curncman »

STAT Webinar: Future directions for cancer immunotherapy

curncman
Posts: 821
Joined: Fri Jun 26, 2020 8:27 am

Cellular Immunotherapy Against CNS Malignancies

Post by curncman »

Cellular Immunotherapy Against CNS Malignancies

curncman
Posts: 821
Joined: Fri Jun 26, 2020 8:27 am

Re: What's The Future of Cancer ImmunotherapNew Hampshire cancer reseay? World Renowned Cancer Expert Shares His Perspec

Post by curncman »

New Hampshire cancer researchers find cellular evidence behind lasting immune response in some cancer survivors

https://us.yahoo.com/news/hampshire-can ... 00430.html

Mar. 26—LEBANON — Researchers at Dartmouth's and Dartmouth-Hitchcock's Norris Cotton Cancer Center (NCCC), New Hampshire's only NCI-designated Comprehensive Cancer Center, have found that a certain subpopulation of cells that enters a patient's skin and blood during immunotherapy is behind the excellent and long-lasting immune responses to cancer that some survivors develop. No prior study has demonstrated cellular evidence of such long-lived immunity to cancer.

Some melanoma patients respond very well to immunotherapy, experiencing profound and durable tumor regression. A fraction of these patients will also develop autoimmunity against their normal melanocytes — the cells that give rise to melanoma — a phenomenon called vitiligo. Melanoma survivors with vitiligo have long been recognized as a special group with an outstanding prognosis, and a strong response of immune system cells called T cells.

Immunotherapy researchers at NCCC, led by Mary Jo Turk, PhD, and surgical oncologist Christina Angeles, MD (now of University of Michigan), have discovered how a subset of T cells known as memory T cells are generated in melanoma survivors with vitiligo and able to function for years after a tumor is gone.

"We are trying to understand how immune responses against cancer can persist over long periods of time in patients who have excellent responses to immunotherapy," says Turk. "Our study was aimed at discovering where T cells go, what they do and how long they last in these patients. Some T cells last a short time, but others, known as memory T cells, can last for years. The goal of this work was to understand how memory T cells are generated in these patients."

The team's findings, entitled "Resident and circulating memory T cells persist for years in melanoma patients with durable responses to immunotherapy," are newly published in Nature Cancer. The extensive collaboration between scientists, surgeons, and oncologists required harvesting tumors, blood, and skin from melanoma patients over a period of several years. Patient specimens were analyzed using state-of-the-art technologies called single cell RNA sequencing and T cell receptor sequencing.

"Finding that T cells can persist for years throughout skin and blood and understanding what defines such durable immune responses in melanoma patients will lead to better design of therapies to achieve such responses," says Turk.

Co-leading this work was Christina Angeles, MD, FACS, who designed and led clinical aspects of the study while at NCCC and serves as co-corresponding author on the paper. Angeles is now a surgical oncologist at Rogel Cancer Center, University of Michigan.

This work was funded by the National Institutes of Health, the American Cancer Society, the Dartmouth CTSA, Dow-Crichlow, the Society of Surgical Oncology, The Knights of the York Cross of Honour and Borroughs Welcome.
curncman
Posts: 821
Joined: Fri Jun 26, 2020 8:27 am

BALLI-01 Study: Is UCART22, an allogeneic anti-CD22 CAR T-cell product, safe and effective?

Post by curncman »

BALLI-01 Study: Is UCART22, an allogeneic anti-CD22 CAR T-cell product, safe and effective?



During the 62nd American Society of Hematology (ASH) Annual Meeting and Exposition, the ALL Hub spoke to Nitin Jain, MD Anderson Cancer Center, Houston, US. We asked, Is UCART22, an allogeneic anti-CD22 CAR T-cell product, safe and effective?

Jain provides an update on a trial evaluating UCART22 in adult patients with relapsed/refractory B-cell ALL. Jain starts by discussing the advantages of using allogeneic T-cell products. He then discusses the safety and efficacy results of the trial and finishes by outlining future adjustments of protocols to promote the persistence of UCART22.
curncman
Posts: 821
Joined: Fri Jun 26, 2020 8:27 am

Targetting cancer with allogeneic NK cell therapies

Post by curncman »

Targeting cancer with allogeneic NK cell therapies



James Trager, PhD, NKarta Therapeutics, South San Francisco, CA, provides an overview of his presentation at the CAR-TCR Summit Europe 2021 on the use of engineered natural killer (NK) cells for allogeneic therapy and describes NKX019, an allogeneic CD19-directed chimeric antigen receptor (CAR)-engineered NK cell, which is being studied preclinically in B cell malignancies. CAR-NK cells have been demonstrated to posses a greater inherent cytotoxicity and reduced risk of cytokine release syndrome compared to CAR-T cells. He also introduces a novel strategy currently under preclinical investigation which involves combining NK and T-cell modalities due to their synergistic properties. This interview took place during the CAR-TCR Summit Europe 2021.



James Trager, PhD, NKarta Therapeutics, South San Francisco, CA, describes NKX019, an investigational allogeneic natural killer (NK) cell-based cancer immunotherapy expanded from healthy donor blood and engineered with a chimeric antigen receptor (CAR) that targets tumors expressing the CD19 antigen for the treatment of B-cell malignancies. NKX019 is also engineered with membrane-bound form of the IL15 cytokine which has been demonstrated to enhance the proliferation and persistence of NK cells in preclinical models. This interview took place during the CAR-TCR Summit Europe 2021.
Last edited by curncman on Sun Mar 28, 2021 11:16 pm, edited 1 time in total.
curncman
Posts: 821
Joined: Fri Jun 26, 2020 8:27 am

Investigating allogeneic iNKT cell therapy

Post by curncman »

Investigating allogeneic iNKT cell therapy



Marc van Dijk, PhD, Agenus, Cambridge, UK, describes INTELLIGENT invariant natural killer T (iNKT) cell technology, which are innate T-cells with natural killer (NK) cell properties, thus giving them the capacity to hone to diseased tissue sites and recruit components of the immune system to fight disease. This off-the-shelf, allogeneic cell therapy is currently being investigated in clinical trials for hematological malignancies such as multiple myeloma (NCT04754100), as well as acute respiratory syndrome in COVID-19 (NCT04582201). Preclinical research has also indicated the ability of iNKT cells to penetrate tissues and therefore their potential for targeting solid tumors, which could be combined with immune checkpoint antibodies in clinical studies in the future. This interview took place during the CAR-TCR Summit Europe 2021.
curncman
Posts: 821
Joined: Fri Jun 26, 2020 8:27 am

What is the difference between Allogenic and Autogeneic Stem Cell Treatments?

Post by curncman »

What is the difference between Allogenic and Autogeneic Stem Cell Treatments?




Find out more about Allogeneic and Autogeneic Stem Cell Treatments with Mr Joyti Saksena, Consultant Hip and Knee Surgeon at Total Orthopaedics and Roberts Shanks at SpinePlus.
Post Reply